Polyrizon Ltd. (NASDAQ: PLRZ) filed a divisional patent application with the European Patent Office on April 27, 2026 for its Trap & Target (T&T) intranasal drug‑delivery platform, expanding the company’s intellectual‑property portfolio in a rapidly growing market.
The filing follows a U.S. patent application that covers Polyrizon’s two core technologies – Capture and Contain (C&C) and Trap & Target (T&T). The T&T platform is engineered to increase the residence time of nasal medications, thereby improving bioavailability and broadening the range of drugs that can be delivered through the nasal route.
Polyrizon’s intranasal drug‑delivery market is projected to reach $120.83 billion by 2032, but more granular estimates show a 2024 market of $70.32 billion, a 2026 market of $2.11 billion, and a 2026 market of $8.1 billion, all growing at double‑digit rates. The patent filing positions Polyrizon to capture a share of this expanding opportunity.
Polyrizon’s technology strategy centers on two platforms. Capture and Contain (C&C) underpins NASARIX, a drug‑free allergy blocker that is advancing toward clinical trials. Trap & Target (T&T) powers intranasal drug‑delivery programs, including a naloxone hydrogel for opioid overdose and potential applications in allergic rhinitis, epilepsy, and other therapeutic areas. Securing European protection for T&T strengthens IP coverage for both platforms and supports future commercialization of NASARIX and other T&T‑based products.
CEO Tomer Izraeli said the filing “marks an important step in strengthening our global intellectual‑property portfolio.” The move underscores Polyrizon’s strategy to protect its hydrogel technology and create a barrier to entry for competitors while advancing its product pipeline.
Investors have shown strong interest in Polyrizon, reflecting confidence in its pipeline and IP strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.